» Articles » PMID: 14531811

Protein Restriction and AST-120 Improve Lipoprotein Lipase and VLDL Receptor in Focal Glomerulosclerosis

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2003 Oct 9
PMID 14531811
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Imai rats exhibit spontaneous focal glomerulosclerosis (FGS) with progressive proteinuria and hyperlipidemia leading to renal insufficiency by age 34 weeks. Recently, we reported marked down-regulations of skeletal muscle and adipose tissue lipoprotein lipase (LPL) and very low-density lipoprotein (VLDL) receptor in male Imai rats at 32 weeks of age. Dietary protein restriction and oral adsorbent AST-120 (AST) have been shown to slow progression of renal disease and attenuate hyperlipidemia in the Imai rats. This study tested the hypothesis that amelioration of proteinuria by protein restriction or use of oral adsorbent AST-120 beginning at 10 weeks of age may improve renal disease and LPL and VLDL receptor deficiencies in Imai rats.

Methods: Ten-week-old male Imai rats were randomly assigned to those fed either a regular diet, low protein diet (LPD), or regular diet containing the adsorbent preparation, AST-120. Ten-week-old male Sprague-Dawley rats served as controls. The animals were observed for 24 weeks. Six rats were included in each group. All diets were prepared in powder form.

Results: The untreated 34-week-old Imai rats showed severe proteinuria, hypoalbuminemia, 50% reduction in creatinine clearance, hypercholesterolemia, hypertriglyceridemia, and elevated plasma VLDL concentration. This was associated with significant reductions in plasma post-heparin LPL activity, hepatic lipase activity, as well as adipose tissue and skeletal muscle immunodetectable LPL and VLDL receptor proteins. Protein restriction mitigated the decline in creatinine clearance, ameliorated proteinuria, hypoalbuminemia, hypertension, and hypercholesterolemia, lowered plasma VLDL, and improved plasma postheparin LPL activity, hepatic lipase activity, LPL, and VLDL receptor proteins in skeletal muscle and adipose tissue. Similar improvements were observed in all parameters with AST administration.

Conclusion: Moderate protein restriction and use of oral adsorbent can slow progression of renal disease and, thereby, ameliorate LPL, hepatic lipase, and VLDL receptor deficiencies and the associated hyperlipidemia in rats with spontaneous FGS.

Citing Articles

High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?.

Liu K, Cooper M, Chai Z, Liu F Int J Mol Sci. 2025; 26(4).

PMID: 40004147 PMC: 11855193. DOI: 10.3390/ijms26041683.


The Ability of AST-120 to Lower the Serum Indoxyl Sulfate Level Improves Renal Outcomes and the Lipid Profile in Diabetic and Nondiabetic Animal Models of Chronic Kidney Disease: A Meta-Analysis.

Altunkaynak H, Karaismailoglu E, Massy Z Toxins (Basel). 2024; 16(12).

PMID: 39728802 PMC: 11679735. DOI: 10.3390/toxins16120544.


HDL and Kidney Diseases.

Cao H, Meng X Adv Exp Med Biol. 2022; 1377:163-170.

PMID: 35575929 DOI: 10.1007/978-981-19-1592-5_13.


Association Between Renal Dysfunction and Low HDL Cholesterol Among the Elderly in China.

You A, Li Y, Tomlinson B, Yue L, Zhao K, Fan H Front Cardiovasc Med. 2021; 8:644208.

PMID: 34055931 PMC: 8149893. DOI: 10.3389/fcvm.2021.644208.


Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation.

Barbagallo C, Cefalu A, Giammanco A, Noto D, Caldarella R, Ciaccio M Life (Basel). 2021; 11(4).

PMID: 33916487 PMC: 8067409. DOI: 10.3390/life11040315.